Search Results - "PRASUGREL"

P2Y 12 Reaction Units With Prasugrel in Acute Large Artery Atherosclerosis and Transient Ischemic Attack: An Open-Label Randomized Controlled Study, ACUTE-PRAS.

Authors: Fujimoto S Iguchi Y Yamagami H et al.

Corporate Authors: Fujimoto S Iguchi Y Yamagami H et al.

Source: Circulation journal : official journal of the Japanese Circulation Society [Circ J] 2025 Nov 25; Vol. 89 (12), pp. 1922-1930. Date of Electronic Publication: 2025 May 16.

Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study

Journal Info: Publisher: Japanese Circulation Society Country of Publication: Japan NLM ID: 101137683 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1347-4820 (Electronic) Linking ISSN: 13469843 NLM ISO Abbreviation: Circ J Subsets: MEDLINE

MeSH Terms: Prasugrel Hydrochloride*/adverse effects , Prasugrel Hydrochloride*/therapeutic use , Prasugrel Hydrochloride*/administration & dosage , Ischemic Attack, Transient*/drug therapy , Ischemic Attack, Transient*/blood , Ischemic Attack, Transient*/genetics , Platelet Aggregation Inhibitors*/adverse effects , Platelet Aggregation Inhibitors*/therapeutic use , Platelet Aggregation Inhibitors*/administration & dosage , Atherosclerosis*/drug therapy , Atherosclerosis*/blood , Purinergic P2Y Receptor Antagonists*/adverse effects , Purinergic P2Y Receptor Antagonists*/therapeutic use , Receptors, Purinergic P2Y12*, Humans ; Male ; Female ; Aged ; Middle Aged ; Cytochrome P-450 CYP2C19/genetics ; Clopidogrel/therapeutic use ; Aspirin/administration & dosage ; Polymorphism, Genetic ; Treatment Outcome

Efficacy and safety of low-dose prasugrel as dual antiplatelet therapy in patients with ischemic heart disease: a systematic review and network meta-analysis of randomized controlled trials.

Authors: Fujii T Amano K Kasai S et al.

Source: Cardiovascular intervention and therapeutics [Cardiovasc Interv Ther] 2025 Oct; Vol. 40 (4), pp. 767-777. Date of Electronic Publication: 2025 Jun 09.

Publication Type: Journal Article; Network Meta-Analysis; Systematic Review

Journal Info: Publisher: Springer Country of Publication: Japan NLM ID: 101522043 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1868-4297 (Electronic) Linking ISSN: 18684297 NLM ISO Abbreviation: Cardiovasc Interv Ther Subsets: MEDLINE

MeSH Terms: Dual Anti-Platelet Therapy*/methods , Myocardial Ischemia*/drug therapy , Platelet Aggregation Inhibitors*/administration & dosage , Platelet Aggregation Inhibitors*/adverse effects , Platelet Aggregation Inhibitors*/therapeutic use , Prasugrel Hydrochloride*/administration & dosage , Prasugrel Hydrochloride*/adverse effects , Prasugrel Hydrochloride*/therapeutic use, Humans ; Dose-Response Relationship, Drug ; Hemorrhage/chemically induced ; Purinergic P2Y Receptor Antagonists/administration & dosage ; Purinergic P2Y Receptor Antagonists/adverse effects ; Randomized Controlled Trials as Topic ; Ticagrelor ; Treatment Outcome

Pharmacodynamic effects of early aspirin withdrawal after percutaneous coronary intervention in patients with atrial fibrillation treated with ticagrelor or prasugrel.

Authors: Sammut MA Rahman MEF Bridge C et al.

Source: Platelets [Platelets] 2025 Dec; Vol. 36 (1), pp. 2507037. Date of Electronic Publication: 2025 May 23.

Publication Type: Journal Article

Journal Info: Publisher: Informa Healthcare Country of Publication: England NLM ID: 9208117 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1369-1635 (Electronic) Linking ISSN: 09537104 NLM ISO Abbreviation: Platelets Subsets: MEDLINE

MeSH Terms: Ticagrelor*/therapeutic use , Ticagrelor*/pharmacology , Percutaneous Coronary Intervention*/methods , Prasugrel Hydrochloride*/therapeutic use , Prasugrel Hydrochloride*/pharmacology , Aspirin*/therapeutic use , Aspirin*/pharmacology , Atrial Fibrillation*/drug therapy , Platelet Aggregation Inhibitors*/therapeutic use , Platelet Aggregation Inhibitors*/pharmacology, Humans ; Male ; Female ; Aged ; Middle Aged ; Prospective Studies

Effectiveness and Safety of Reduced-Dose Prasugrel in an East Asian Population: PRASFIT-ACS Emulation Using National Health Insurance Claims Data.

Authors: Huang LW Wu YJ Lin FJ et al.

Source: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2025 Nov; Vol. 118 (5), pp. 1170-1179. Date of Electronic Publication: 2025 Aug 04.

Publication Type: Journal Article

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE

MeSH Terms: Prasugrel Hydrochloride*/administration & dosage , Prasugrel Hydrochloride*/adverse effects , Acute Coronary Syndrome*/drug therapy , Acute Coronary Syndrome*/therapy , Acute Coronary Syndrome*/diagnosis , Acute Coronary Syndrome*/ethnology , Platelet Aggregation Inhibitors*/administration & dosage , Platelet Aggregation Inhibitors*/adverse effects , Percutaneous Coronary Intervention*/adverse effects, Humans ; Male ; Female ; Retrospective Studies ; Middle Aged ; Aged ; Clopidogrel/administration & dosage ; Clopidogrel/adverse effects ; Hemorrhage/chemically induced ; Taiwan/epidemiology ; Treatment Outcome ; National Health Programs ; Asian People ; Insurance Claim Review ; East Asian People

Stent-assisted coiling and flow diversion with hpc-coated devices under prasugrel monotherapy in ruptured wide-neck aneurysms: a multicenter case series.

Authors: Aburub A Felber S Henkes H et al.

Source: Neuroradiology [Neuroradiology] 2025 Sep; Vol. 67 (9), pp. 2505-2518. Date of Electronic Publication: 2025 Jul 21.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 1302751 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1920 (Electronic) Linking ISSN: 00283940 NLM ISO Abbreviation: Neuroradiology Subsets: MEDLINE

MeSH Terms: Intracranial Aneurysm*/therapy , Intracranial Aneurysm*/diagnostic imaging , Aneurysm, Ruptured*/therapy , Aneurysm, Ruptured*/diagnostic imaging , Prasugrel Hydrochloride*/therapeutic use , Prasugrel Hydrochloride*/administration & dosage , Platelet Aggregation Inhibitors*/therapeutic use , Embolization, Therapeutic*/methods , Embolization, Therapeutic*/instrumentation , Drug-Eluting Stents* , Stents*, Humans ; Male ; Middle Aged ; Female ; Retrospective Studies ; Treatment Outcome ; Aged ; Adult ; Cerebral Angiography

Optimal antiplatelet therapy in patients with acute coronary syndrome and chronic kidney disease: for the Jerusalem platelets thrombosis and intervention in cardiology (JUPITER-11) study group.

Authors: Nimrod P David M Louay T et al.

Source: BMC nephrology [BMC Nephrol] 2025 Aug 04; Vol. 26 (1), pp. 429. Date of Electronic Publication: 2025 Aug 04.

Publication Type: Journal Article

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100967793 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2369 (Electronic) Linking ISSN: 14712369 NLM ISO Abbreviation: BMC Nephrol Subsets: MEDLINE

MeSH Terms: Renal Insufficiency, Chronic*/complications , Renal Insufficiency, Chronic*/drug therapy , Platelet Aggregation Inhibitors*/therapeutic use , Platelet Aggregation Inhibitors*/adverse effects , Acute Coronary Syndrome*/drug therapy , Acute Coronary Syndrome*/complications , Acute Coronary Syndrome*/mortality , Prasugrel Hydrochloride*/therapeutic use , Prasugrel Hydrochloride*/adverse effects, Humans ; Female ; Male ; Clopidogrel/therapeutic use ; Ticagrelor/therapeutic use ; Middle Aged ; Aged ; Hemorrhage/chemically induced ; Hemorrhage/epidemiology ; ST Elevation Myocardial Infarction/drug therapy ; Israel/epidemiology ; Glomerular Filtration Rate ; Treatment Outcome

Preventive Effects of Prasugrel on Cerebrovascular Events Following Percutaneous Coronary Intervention.

Authors: Makimoto H Sasabuchi Y Kabutoya T et al.

Corporate Authors: Makimoto H Sasabuchi Y Kabutoya T et al.

Source: Stroke [Stroke] 2025 Aug; Vol. 56 (8), pp. 2101-2109. Date of Electronic Publication: 2025 May 23.

Publication Type: Journal Article

Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0235266 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1524-4628 (Electronic) Linking ISSN: 00392499 NLM ISO Abbreviation: Stroke Subsets: MEDLINE

MeSH Terms: Prasugrel Hydrochloride*/therapeutic use , Percutaneous Coronary Intervention*/adverse effects , Platelet Aggregation Inhibitors*/therapeutic use , Cerebrovascular Disorders*/prevention & control , Cerebrovascular Disorders*/epidemiology, Humans ; Male ; Female ; Aged ; Middle Aged ; Clopidogrel/therapeutic use ; Japan/epidemiology ; Incidence

One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial.

Authors: Jang Y Park SD Lee JP et al.

Source: EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology [EuroIntervention] 2025 Jul 21; Vol. 21 (14), pp. e796-e809. Date of Electronic Publication: 2025 Jul 21.

Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study

Journal Info: Publisher: Société Europa édition Country of Publication: France NLM ID: 101251040 Publication Model: Electronic Cited Medium: Internet ISSN: 1969-6213 (Electronic) Linking ISSN: 1774024X NLM ISO Abbreviation: EuroIntervention Subsets: MEDLINE

MeSH Terms: Prasugrel Hydrochloride*/administration & dosage , Prasugrel Hydrochloride*/therapeutic use , Prasugrel Hydrochloride*/adverse effects , Acute Coronary Syndrome*/drug therapy , Acute Coronary Syndrome*/therapy , Platelet Aggregation Inhibitors*/administration & dosage , Platelet Aggregation Inhibitors*/therapeutic use , Platelet Aggregation Inhibitors*/adverse effects , Aspirin*/administration & dosage , Aspirin*/therapeutic use , Aspirin*/adverse effects , Dual Anti-Platelet Therapy*/methods , Percutaneous Coronary Intervention*/methods, Humans ; Male ; Female ; Aged ; Middle Aged ; Treatment Outcome ; Drug-Eluting Stents ; Drug Therapy, Combination ; Hemorrhage/chemically induced

Aspirin-Free Strategy for PCI in Patients With High Bleeding Risk With or Without Acute Coronary Syndrome: A Subgroup Analysis From the STOPDAPT-3 Trial.

Authors: Ishikawa T Natsuaki M Watanabe H et al.

Source: Circulation. Cardiovascular interventions [Circ Cardiovasc Interv] 2025 Jul; Vol. 18 (7), pp. e015197. Date of Electronic Publication: 2025 May 14.

Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study; Comparative Study

Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 101499602 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-7632 (Electronic) Linking ISSN: 19417640 NLM ISO Abbreviation: Circ Cardiovasc Interv Subsets: MEDLINE

MeSH Terms: Acute Coronary Syndrome*/therapy , Acute Coronary Syndrome*/mortality , Acute Coronary Syndrome*/diagnostic imaging , Coronary Artery Disease*/therapy , Coronary Artery Disease*/mortality , Coronary Artery Disease*/diagnostic imaging , Hemorrhage*/chemically induced , Hemorrhage*/epidemiology , Hemorrhage*/prevention & control , Percutaneous Coronary Intervention*/adverse effects , Percutaneous Coronary Intervention*/mortality , Percutaneous Coronary Intervention*/instrumentation , Platelet Aggregation Inhibitors*/adverse effects , Platelet Aggregation Inhibitors*/administration & dosage , Prasugrel Hydrochloride*/adverse effects , Prasugrel Hydrochloride*/administration & dosage, Aged ; Female ; Humans ; Male ; Middle Aged ; Aspirin/administration & dosage ; Aspirin/adverse effects ; Dual Anti-Platelet Therapy/adverse effects ; Dual Anti-Platelet Therapy/mortality ; Risk Assessment ; Risk Factors ; Time Factors ; Treatment Outcome

Flow diversion with hydrophilic polymer coating with prasugrel as single antiplatelet therapy in the treatment of acutely ruptured intracranial aneurysms: a multicenter case series, complication and occlusion rates.

Authors: Khanafer A Lobsien D Sirakov A et al.

Source: Journal of neurointerventional surgery [J Neurointerv Surg] 2025 Jul 14; Vol. 17 (8), pp. 870-877. Date of Electronic Publication: 2025 Jul 14.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: BMJ Publishing Group Country of Publication: England NLM ID: 101517079 Publication Model: Electronic Cited Medium: Internet ISSN: 1759-8486 (Electronic) Linking ISSN: 17598478 NLM ISO Abbreviation: J Neurointerv Surg Subsets: MEDLINE

MeSH Terms: Prasugrel Hydrochloride*/administration & dosage , Intracranial Aneurysm*/diagnostic imaging , Intracranial Aneurysm*/drug therapy , Intracranial Aneurysm*/therapy , Platelet Aggregation Inhibitors*/administration & dosage , Aneurysm, Ruptured*/diagnostic imaging , Aneurysm, Ruptured*/drug therapy , Aneurysm, Ruptured*/therapy , Polymers*/administration & dosage, Humans ; Female ; Middle Aged ; Male ; Aged ; Adult ; Subarachnoid Hemorrhage ; Treatment Outcome ; Prospective Studies ; Follow-Up Studies ; Endovascular Procedures/methods ; Hydrophobic and Hydrophilic Interactions

Prasugrel Intermediate Metabolite Modulates Platelet Inhibition by Negatively Interfering With an Active Metabolite: An Ex Vivo, In Vitro, and In Silico Study.

Authors: Minuz P Giorgetti A Meneguzzi A et al.

Source: Arteriosclerosis, thrombosis, and vascular biology [Arterioscler Thromb Vasc Biol] 2025 May; Vol. 45 (5), pp. 792-804. Date of Electronic Publication: 2025 Mar 20.

Publication Type: Clinical Trial, Phase IV; Journal Article; Multicenter Study; Randomized Controlled Trial

Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9505803 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1524-4636 (Electronic) Linking ISSN: 10795642 NLM ISO Abbreviation: Arterioscler Thromb Vasc Biol Subsets: MEDLINE

MeSH Terms: Blood Platelets*/drug effects , Blood Platelets*/metabolism , Platelet Aggregation*/drug effects , Platelet Aggregation Inhibitors*/pharmacokinetics , Platelet Aggregation Inhibitors*/blood , Platelet Aggregation Inhibitors*/administration & dosage , Prasugrel Hydrochloride*/pharmacokinetics , Prasugrel Hydrochloride*/blood , Prasugrel Hydrochloride*/administration & dosage , Prasugrel Hydrochloride*/metabolism , Purinergic P2Y Receptor Antagonists*/pharmacokinetics , Purinergic P2Y Receptor Antagonists*/blood , Purinergic P2Y Receptor Antagonists*/administration & dosage , ST Elevation Myocardial Infarction*/blood , ST Elevation Myocardial Infarction*/drug therapy , ST Elevation Myocardial Infarction*/diagnosis , ST Elevation Myocardial Infarction*/therapy, Aged ; Female ; Humans ; Male ; Middle Aged ; Administration, Oral ; Binding Sites ; Cell Adhesion Molecules/blood ; Microfilament Proteins/blood ; Molecular Docking Simulation ; Molecular Dynamics Simulation ; Phosphoproteins/blood ; Phosphorylation ; Platelet Activation/drug effects ; Receptors, Purinergic P2Y12/drug effects ; Receptors, Purinergic P2Y12/blood ; Vasodilator-Stimulated Phosphoprotein ; Piperazines ; P-Selectin

Exploring the relationship of platelet aggregation function with efficacy and safety outcomes following the administration of prasugrel and clopidogrel in patients with thrombotic stroke: a post hoc analysis of PRASTRO pooled studies.

Authors: Kimura K Kamouchi M Matsumaru Y et al.

Source: Journal of thrombosis and thrombolysis [J Thromb Thrombolysis] 2025 Apr; Vol. 58 (4), pp. 547-555. Date of Electronic Publication: 2025 Apr 14.

Publication Type: Journal Article

Journal Info: Publisher: Kluwer Academic Publishers Country of Publication: Netherlands NLM ID: 9502018 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-742X (Electronic) Linking ISSN: 09295305 NLM ISO Abbreviation: J Thromb Thrombolysis Subsets: MEDLINE

MeSH Terms: Prasugrel Hydrochloride*/adverse effects , Prasugrel Hydrochloride*/therapeutic use , Prasugrel Hydrochloride*/administration & dosage , Clopidogrel*/adverse effects , Clopidogrel*/therapeutic use , Clopidogrel*/administration & dosage , Stroke*/drug therapy , Stroke*/blood , Platelet Aggregation Inhibitors*/adverse effects , Platelet Aggregation Inhibitors*/therapeutic use , Platelet Aggregation Inhibitors*/administration & dosage , Platelet Aggregation*/drug effects , Thrombosis*/drug therapy , Thrombosis*/blood, Humans ; Male ; Female ; Middle Aged ; Aged ; Treatment Outcome ; Risk Factors ; Hemorrhage/chemically induced ; Purinergic P2Y Receptor Antagonists/adverse effects ; Purinergic P2Y Receptor Antagonists/therapeutic use

Cost-effectiveness of implementing a genotype-guided de-escalation strategy in patients with acute coronary syndrome.

Authors: van den Broek WWA Azzahhafi J Chan Pin Yin DRPP et al.

Source: European heart journal. Cardiovascular pharmacotherapy [Eur Heart J Cardiovasc Pharmacother] 2025 May 02; Vol. 11 (3), pp. 230-240.

Publication Type: Comparative Study; Journal Article; Observational Study

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 101669491 Publication Model: Print Cited Medium: Internet ISSN: 2055-6845 (Electronic) NLM ISO Abbreviation: Eur Heart J Cardiovasc Pharmacother Subsets: MEDLINE

MeSH Terms: Acute Coronary Syndrome*/economics , Acute Coronary Syndrome*/drug therapy , Acute Coronary Syndrome*/diagnosis , Acute Coronary Syndrome*/genetics , Cytochrome P-450 CYP2C19*/genetics , Cytochrome P-450 CYP2C19*/metabolism , Drug Costs* , Drug Substitution*/economics , Dual Anti-Platelet Therapy*/economics , Dual Anti-Platelet Therapy*/adverse effects , Pharmacogenomic Testing*/economics , Pharmacogenomic Variants* , Platelet Aggregation Inhibitors*/adverse effects , Platelet Aggregation Inhibitors*/economics , Platelet Aggregation Inhibitors*/administration & dosage , Prasugrel Hydrochloride*/adverse effects , Prasugrel Hydrochloride*/economics , Prasugrel Hydrochloride*/administration & dosage , Purinergic P2Y Receptor Antagonists*/adverse effects , Purinergic P2Y Receptor Antagonists*/economics , Purinergic P2Y Receptor Antagonists*/administration & dosage, Aged ; Female ; Humans ; Male ; Middle Aged ; Clopidogrel/adverse effects ; Clopidogrel/economics ; Clopidogrel/administration & dosage ; Cost Savings ; Cost-Benefit Analysis ; Decision Trees ; Hemorrhage/chemically induced ; Hemorrhage/economics ; Markov Chains ; Models, Economic ; Netherlands ; Phenotype ; Precision Medicine/economics ; Quality-Adjusted Life Years ; Registries ; Risk Factors ; Ticagrelor/adverse effects ; Ticagrelor/economics ; Ticagrelor/administration & dosage ; Time Factors ; Treatment Outcome

Prasugrel monotherapy versus standard DAPT in STEMI patients with OCT-guided or angio-guided complete revascularisation: design and rationale of the randomised, multifactorial COMPARE STEMI ONE trial.

Authors: Paradies V Van Mieghem NM Oemrawsingh RM et al.

Source: EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology [EuroIntervention] 2025 May 16; Vol. 21 (10), pp. 571-580.

Publication Type: Journal Article; Clinical Trial Protocol; Randomized Controlled Trial; Multicenter Study; Comparative Study

Journal Info: Publisher: Société Europa édition Country of Publication: France NLM ID: 101251040 Publication Model: Print Cited Medium: Internet ISSN: 1969-6213 (Electronic) Linking ISSN: 1774024X NLM ISO Abbreviation: EuroIntervention Subsets: MEDLINE

MeSH Terms: Prasugrel Hydrochloride*/therapeutic use , ST Elevation Myocardial Infarction*/therapy , ST Elevation Myocardial Infarction*/drug therapy , ST Elevation Myocardial Infarction*/diagnostic imaging , ST Elevation Myocardial Infarction*/surgery , Tomography, Optical Coherence*/methods , Percutaneous Coronary Intervention*/methods , Platelet Aggregation Inhibitors*/therapeutic use , Purinergic P2Y Receptor Antagonists*/therapeutic use, Humans ; Treatment Outcome ; Coronary Angiography/methods ; Randomized Controlled Trials as Topic ; Male

Strategies to optimize initial P2Y 12 inhibitor therapy in STEMI patients.

Authors: Millhuff AC Blankenship JC

Source: Cardiovascular revascularization medicine : including molecular interventions [Cardiovasc Revasc Med] 2025 Feb; Vol. 71, pp. 43-49. Date of Electronic Publication: 2024 Sep 25.

Publication Type: Journal Article; Review

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101238551 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0938 (Electronic) Linking ISSN: 18780938 NLM ISO Abbreviation: Cardiovasc Revasc Med Subsets: MEDLINE

MeSH Terms: ST Elevation Myocardial Infarction*/therapy , ST Elevation Myocardial Infarction*/blood , ST Elevation Myocardial Infarction*/diagnosis , ST Elevation Myocardial Infarction*/diagnostic imaging , Purinergic P2Y Receptor Antagonists*/administration & dosage , Purinergic P2Y Receptor Antagonists*/adverse effects , Ticagrelor*/administration & dosage , Ticagrelor*/adverse effects , Percutaneous Coronary Intervention*/adverse effects , Prasugrel Hydrochloride*/administration & dosage , Prasugrel Hydrochloride*/adverse effects , Platelet Aggregation Inhibitors*/administration & dosage , Platelet Aggregation Inhibitors*/adverse effects , Blood Platelets*/drug effects , Blood Platelets*/metabolism , Receptors, Purinergic P2Y12*/drug effects , Receptors, Purinergic P2Y12*/blood, Humans ; Treatment Outcome ; Risk Factors ; Administration, Oral ; Time Factors ; Drug Administration Schedule ; Dual Anti-Platelet Therapy/adverse effects

Simultaneous estimation of prasugrel and aspirin in bulk drugs by chemometric methods.

Authors: Desai U Christian J Suhagia BN

Source: Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy [Spectrochim Acta A Mol Biomol Spectrosc] 2025 Feb 15; Vol. 327, pp. 125306. Date of Electronic Publication: 2024 Oct 22.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9602533 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3557 (Electronic) Linking ISSN: 13861425 NLM ISO Abbreviation: Spectrochim Acta A Mol Biomol Spectrosc Subsets: MEDLINE

MeSH Terms: Prasugrel Hydrochloride*/analysis , Aspirin*/analysis , Principal Component Analysis*, Least-Squares Analysis ; Spectrophotometry, Ultraviolet/methods ; Reproducibility of Results ; Limit of Detection ; Bulk Drugs

An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial.

Authors: Yamamoto K Natsuaki M Watanabe H et al.

Source: European heart journal. Cardiovascular pharmacotherapy [Eur Heart J Cardiovasc Pharmacother] 2025 Feb 08; Vol. 11 (1), pp. 34-44.

Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 101669491 Publication Model: Print Cited Medium: Internet ISSN: 2055-6845 (Electronic) NLM ISO Abbreviation: Eur Heart J Cardiovasc Pharmacother Subsets: MEDLINE

MeSH Terms: Acute Coronary Syndrome*/therapy , Acute Coronary Syndrome*/mortality , Acute Coronary Syndrome*/diagnosis , Acute Coronary Syndrome*/diagnostic imaging , Coronary Artery Disease*/therapy , Coronary Artery Disease*/mortality , Coronary Artery Disease*/diagnostic imaging , Diabetes Mellitus*/mortality , Diabetes Mellitus*/diagnosis , Diabetes Mellitus*/epidemiology , Dual Anti-Platelet Therapy*/adverse effects , Dual Anti-Platelet Therapy*/mortality , Percutaneous Coronary Intervention*/adverse effects , Percutaneous Coronary Intervention*/mortality , Percutaneous Coronary Intervention*/instrumentation , Prasugrel Hydrochloride*/adverse effects , Prasugrel Hydrochloride*/administration & dosage, Aged ; Female ; Humans ; Male ; Middle Aged ; Aspirin/adverse effects ; Aspirin/administration & dosage ; Hemorrhage/chemically induced ; Platelet Aggregation Inhibitors/adverse effects ; Platelet Aggregation Inhibitors/administration & dosage ; Risk Assessment ; Risk Factors ; Time Factors ; Treatment Outcome

Genotype-Guided P2Y 12 Inhibitor Monotherapy Within 7 Days of Percutaneous Coronary Intervention in High Bleeding Risk Patients: The CHAMP Trial - A Pilot Study and Safety Assessment.

Authors: Ingraham BS Huxley SB Lane CM et al.

Source: Mayo Clinic proceedings [Mayo Clin Proc] 2025 Jan; Vol. 100 (1), pp. 94-108. Date of Electronic Publication: 2024 Nov 26.

Publication Type: Journal Article

Journal Info: Publisher: [Oxford, England] Country of Publication: England NLM ID: 0405543 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1942-5546 (Electronic) Linking ISSN: 00256196 NLM ISO Abbreviation: Mayo Clin Proc Subsets: MEDLINE

MeSH Terms: Percutaneous Coronary Intervention*/methods , Purinergic P2Y Receptor Antagonists*/therapeutic use , Purinergic P2Y Receptor Antagonists*/adverse effects , Purinergic P2Y Receptor Antagonists*/administration & dosage , Clopidogrel*/therapeutic use , Clopidogrel*/adverse effects , Cytochrome P-450 CYP2C19*/genetics , Ticagrelor*/therapeutic use , Ticagrelor*/adverse effects , Prasugrel Hydrochloride*/therapeutic use , Prasugrel Hydrochloride*/adverse effects , Prasugrel Hydrochloride*/administration & dosage , Genotype* , Aspirin*/therapeutic use , Aspirin*/administration & dosage , Aspirin*/adverse effects, Humans ; Female ; Pilot Projects ; Male ; Aged ; Middle Aged ; Hemorrhage/chemically induced ; Platelet Aggregation Inhibitors/therapeutic use ; Platelet Aggregation Inhibitors/adverse effects ; Feasibility Studies

One-year clinical outcomes in patients with acute coronary syndrome treated with clopidogrel versus prasugrel versus ticagrelor: Results of the Polish Registry of Acute Coronary Syndromes (PL-ACS).

Authors: Umińska JM Skrzypek M Ostrowska M et al.

Source: Kardiologia polska [Kardiol Pol] 2025; Vol. 83 (10), pp. 1142-1151. Date of Electronic Publication: 2025 Jul 29.

Publication Type: Journal Article; Comparative Study

Journal Info: Publisher: Via Medica Country of Publication: Poland NLM ID: 0376352 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1897-4279 (Electronic) Linking ISSN: 00229032 NLM ISO Abbreviation: Kardiol Pol Subsets: MEDLINE

MeSH Terms: Ticagrelor*/therapeutic use , Prasugrel Hydrochloride*/therapeutic use , Acute Coronary Syndrome*/drug therapy , Acute Coronary Syndrome*/mortality , Clopidogrel*/therapeutic use , Platelet Aggregation Inhibitors*/therapeutic use, Humans ; Male ; Female ; Poland ; Middle Aged ; Registries ; Aged ; Retrospective Studies ; Treatment Outcome

Balancing the Interactions: Assessing Antiplatelet and Antiretroviral Therapy Drug-Drug Interactions in People Living With HIV.

Authors: Matsikas A Marsh K Huynh Q et al.

Source: Journal of cardiovascular pharmacology [J Cardiovasc Pharmacol] 2025 Jan 01; Vol. 85 (1), pp. 75-83. Date of Electronic Publication: 2025 Jan 01.

Publication Type: Journal Article

Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 7902492 Publication Model: Electronic Cited Medium: Internet ISSN: 1533-4023 (Electronic) Linking ISSN: 01602446 NLM ISO Abbreviation: J Cardiovasc Pharmacol Subsets: MEDLINE

MeSH Terms: Platelet Aggregation Inhibitors*/adverse effects , Platelet Aggregation Inhibitors*/administration & dosage , HIV Infections*/drug therapy , HIV Infections*/diagnosis , HIV Infections*/epidemiology , HIV Infections*/blood , Purinergic P2Y Receptor Antagonists*/adverse effects , Purinergic P2Y Receptor Antagonists*/administration & dosage , Prasugrel Hydrochloride*/adverse effects , Prasugrel Hydrochloride*/administration & dosage , Anti-HIV Agents*/adverse effects , Ticagrelor*/adverse effects, Humans ; Drug Interactions ; Retrospective Studies ; Male ; Female ; Middle Aged ; Hemorrhage/chemically induced ; Hemorrhage/epidemiology ; Adult ; Treatment Outcome ; Risk Factors ; Risk Assessment ; Clopidogrel/adverse effects ; Incidence ; Drug Substitution ; Time Factors ; Thrombosis/epidemiology ; Thrombosis/diagnosis ; Thrombosis/prevention & control